Biocept

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.

Biocept Inc (NASDAQ:BIOC) (FRA:B003) has expanded its board of directors to nine members from seven and named director since 2020 Samuel D Riccitelli as the company's new chairman as the diagnostics group builds on recent momentum. Experienced financial executives Linda Rubinstein and Antonino Morales become new directors with immediate effect.

Biocept bolsters board of directors and names Samuel D Riccitelli as new chairman

SAN DIEGO--(BUSINESS WIRE)--Biocept appointed Linda Rubinstein and Antonino Morales to its Board of Directors, and named Director Samuel D. Riccitelli as Chairman of the Board.

Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will participate at the following investment conferences: Brookline Capital Markets Newport Symposium, “Transformative Biotech – Cancer, Rare Diseases, and Viruses,” which will feature group and one-on-one investor meetings and panel discussions with scientific and industry experts. The conference is being held in New

Biocept to Participate in Two July Investment Conferences

SAN DIEGO--(BUSINESS WIRE)-- #cancer--Biocept was awarded a South Korean Patent for its Primer-Switch technology, which identifies rare genetic mutations, including cancer biomarkers.

Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers

Biocept Inc (NASDAQ:BIOC) (FRA:B003) announced that it was added to the Russell Microcap Index as the US market opened on June 28, 2021.  The Russell Microcap Index is a broadly used performance benchmark for smaller growth stocks in the US.

Biocept joins the Russell Microcap Index

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #Russell_Microcap_Index--Biocept joins the Russell Microcap Index

Biocept Joins the Russell Microcap® Index

Quest Diagnostics

Biocept Inc (NASDAQ:BIOC) (FRA:B003) has announced a collaboration with Quest Diagnostics Inc (NYSE:DGX) (FRA:QDI) to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid biopsy targeted lung cancer panel.   Biocept said both companies expect the service to be available to Quest's providers and patients in the fourth quarter of 2021.

Biocept partners with Quest Diagnostics to provide its Target Selector NGS-based liquid biopsy testing for lung cancer

SAN DIEGO--(BUSINESS WIRE)--Biocept and Quest Diagnostics collaborate to provide NGS-based liquid biopsy testing to aid therapy selection and monitoring for lung cancer patients.

Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer

Biocept Inc (NASDAQ:BIOC) (FRA:B003) revealed to investors that it has received more than 420,000 samples for coronavirus testing since launching the service in June 2020.   The samples are processed using Biocept's RT-PCR-based technology at its CLIA-certified, CAP-accredited, high-complexity molecular laboratory in San Diego.

Biocept says it has received 240,000 coronavirus tests since June 2020; readies flu testing for the fall

SAN DIEGO--(BUSINESS WIRE)--Biocept received more than 420,000 samples for COVID-19 testing since launching service in June 2020.

Biocept Receives More Than 420,000 Samples During First Year of Offering COVID-19 Testing Service

SAN DIEGO--(BUSINESS WIRE)--Biocept and CLEARED4 to develop new system for tracking and managing COVID-19 testing for campuses and other facilities returning to full capacity.

Biocept and CLEARED4 Collaborate to Develop New Service for Managing COVID-19 Testing and Results Reporting for Biocept Customers

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time). “We look forward to providing investors with an update on CNSide™, our novel assay that provides physicians with a significantly improved tool to diagnose and manage patients with tumors

Biocept to Present at the LD Micro Virtual Invitational XI Conference on June 9, 2021

Biocept Inc (NASDAQ:BIOC) (FRA:B003) started 2021 on a high with a profitable first quarter on revenue of $17.8 million, driven primarily by its coronavirus (COVID-19) tests.  For the period ended March 31, 2020, the San Diego-based company, which develops molecular diagnostic assays, posted revenue of $17.8 million, compared with $1.4 million for the first quarter of 2020.

Biocept starts 2021 on a high with a profitable 1Q on revenue of $17.8M, driven by its coronavirus tests

Biocept, Inc. (BIOC) CEO Michael Nall on Q1 2021 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #Biocept--Biocept reports profitability for the second consecutive quarter on revenues of $17.8 million for the first quarter of 2021.

Biocept Reports First Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three months ended March 31, 2021 after the market closes on Wednesday, May 12, 2021. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Date/Time: Wednesday, May 12, 4:30 p.m. ET / 1:30 p.m. PT

Biocept to Report First Quarter 2021 Financial Results and Host Investor Conference Call on May 12, 2021

Biocept Inc (NASDAQ:BIOC) has said it is partnering with the Foundation for California Community Colleges to make coronavirus (COVID-19) testing available for the state‘s 116 community colleges and their more than 2.1 million students. Through the Foundation's CollegeBuys program, Biocept said its PCR-based COVID-19 test is now available for community colleges to purchase for students, faculty, and staff.

Biocept makes coronavirus testing available for California's 116 community colleges

SAN DIEGO--(BUSINESS WIRE)--Biocept to provide COVID-19 testing to California community colleges and their more than 2.1 million students through FCCC partnership.

Biocept to Supply COVID-19 Testing Through Partnership With the Foundation for California Community Colleges

Biocept Inc (NASDAQ:BIOC) (FRA:B003) announced the full commercial launch of CNSide, the company's cerebrospinal fluid (CSF) assay designed to better detect and manage the treatment of metastatic cancers involving the central nervous system (CNS).   The company said the assay, which was initially introduced in January 2020, has the ability to offer a timely and accurate method to diagnose disease, identify actionable biomarkers, and assess response to therapy, potentially impacting life expectancy and quality of life.

Biocept launches its CNSide cerebrospinal fluid assay for early detection of metastatic brain cancer

SAN DIEGO--(BUSINESS WIRE)-- #cancer--Biocept announces full launch of CNSide, its CSF assay designed to improve the management of metastatic cancers involving the central nervous system.

Biocept Announces Full Commercial Launch of CNSide™ Cerebrospinal Fluid Assay to Address Unmet Needs for Patients with Metastatic Brain Cancer

Biocept Inc (NASDAQ:BIOC) (FRA:B003) reports that since the company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples.   These test samples are processed using Biocept's RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory in San Diego.

Biocept says its lab received to-date more than 350,000 coronavirus testing samples for processing

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #Biocept--Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date

Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date

Biocept has been hard at work processing thousands of COVID-19 tests per week. As a result, the company reported its first profitable quarter and record full-year revenues.

Biocept: Record Revenues And Profits Support Speculative Buy

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) will host a webinar featuring leading neuro-oncologists to discuss the use of the Company's proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain or spinal column. Biocept's CSF assay provides enhanced sensitivity compared with CSF cytology, the current standard of care, and has the added advantage of identifying actionable molecular t

Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System

Biocept Inc (NASDAQ:BIOC) (FRA:B003) will host a webinar featuring leading neuro-oncologists to discuss the use of its proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain or spinal column.   The company said its CSF assay provides enhanced sensitivity compared with CSF cytology, the current standard-of-care, and has the added advantage of identifying actionable molecular targets for use in treatment decisions while providing quantitative information needed for assessing treatment response and monitoring disease progression.

News for Biocept Stock (BIOC)